Testing effectiveness (Phase 2)Study completedNCT01105403What this trial is testingExploratory Study on POL6326 in Stem Cell MobilizationWho this might be right forMultiple Myeloma Polyphor Ltd. 21
Testing effectiveness (Phase 2)Study completedNCT00576979What this trial is testingIntensity-Modulated Radiation Therapy, Etoposide, and Cyclophosphamide Followed By Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid LeukemiaWho this might be right forLeukemia City of Hope Medical Center 51
Testing effectiveness (Phase 2)Study completedNCT01753453What this trial is testingAn Exploratory Safety Study to Investigate the Extent of Tumor Cell Mobilization (TCM) After Use of G-CSF Alone or G-CSF Plus Plerixafor in Multiple Myeloma (MM) Patients Who May be Poor Mobilizers of Stem CellsWho this might be right forMultiple Myeloma Sanofi 23
Not applicableActive Not RecruitingNCT05359237What this trial is testingVincristine Pharmacokinetics in InfantsWho this might be right forHematopoietic and Lymphoid Cell NeoplasmMalignant Solid Neoplasm Children's Oncology Group 83
Not applicableStudy completedNCT04364256What this trial is testingMuscle Stimulation for Physical Function During Stem Cell TransplantWho this might be right forAutologous Hematopoietic Stem Cell Transplant VA Office of Research and Development 46
Not applicableEnded earlyNCT00507572What this trial is testingCollection of Outcomes Data for Pregnant Patients With CancerWho this might be right forHematopoietic and Lymphoid Cell NeoplasmMalignant Solid Neoplasm M.D. Anderson Cancer Center 313
Not applicableUnknownNCT02184897What this trial is testingPharmacokinetic and Pharmacodynamic Study of Lenograstim for Hematopoietic Stem Cell MobilizationWho this might be right forMultiple Myeloma Asan Medical Center 24
Testing effectiveness (Phase 2)Enrolling By InvitationNCT07775313What this trial is testingBase-Edited Hematopoietic Stem/Progenitor Cell Gene Therapy for Treatment of CXCR4-WHIMWho this might be right forWHIMWartsHypogammaglobulinemia+2 more National Institute of Allergy and Infectious Diseases (NIAID) 10
Not applicableActive Not RecruitingNCT04196972What this trial is testingTelementoring Intervention (ECHO) for the Transformation of Professional Engagement, Practice Efficiency, and Community Building Through Team Meetings in Diagnostic Imaging CliniciansWho this might be right forHematopoietic and Lymphoid Cell NeoplasmMalignant Solid Neoplasm M.D. Anderson Cancer Center 36
Not applicableLooking for participantsNCT06111612What this trial is testingIntensive Conditioning withTHI/Bu/Flu/Ara-C in Allo-HSCT for Myeloid Malignancies With Extramedullary InvolvementWho this might be right forAcute Myeloid LeukemiaMyelodysplastic NeoplasmChronic Myelomonocytic Leukemia+2 more Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine 50
Large-scale testing (Phase 3)Study completedNCT00382109What this trial is testingTacrolimus and Methotrexate With or Without Sirolimus in Preventing Graft-Versus-Host Disease in Young Patients Undergoing Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia in Complete RemissionWho this might be right forB-cell Childhood Acute Lymphoblastic LeukemiaChildhood Acute Lymphoblastic Leukemia in RemissionGraft Versus Host Disease+3 more Children's Oncology Group 146
Testing effectiveness (Phase 2)Study completedNCT00003887What this trial is testingLymphocyte Infusion in Treating Patients With Relapsed Cancer After Bone Marrow or Peripheral Stem Cell TransplantationWho this might be right forBreast CancerChronic Myeloproliferative DisordersGestational Trophoblastic Tumor+9 more Fred Hutchinson Cancer Center
Not applicableEnrolling By InvitationNCT07215039What this trial is testingImproving Prison Health Equity Through Cancer Literacy and Screening Awareness in FloridaWho this might be right forHematopoietic and Lymphatic System NeoplasmMalignant Solid Neoplasm Mayo Clinic 1,200
Testing effectiveness (Phase 2)Ended earlyNCT00720629What this trial is testingVisilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell TransplantationWho this might be right forGraft Versus Host Disease H. Lee Moffitt Cancer Center and Research Institute 8
Testing effectiveness (Phase 2)Active Not RecruitingNCT04439175What this trial is testingTesting GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)Who this might be right forAdvanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm+3 more National Cancer Institute (NCI) 70
Testing effectiveness (Phase 2)Study completedNCT01386619What this trial is testingNK DLI in Patients After Human Leukocyte Antigen (HLA)-Haploidentical Hematopoietic Stem Cell Transplantation (HSCT)Who this might be right forLeukemia, Myeloid, AcutePrecursor Cell Lymphoblastic Leukemia-LymphomaMyelodysplastic Syndromes+3 more University Hospital, Basel, Switzerland 15
Testing effectiveness (Phase 2)Study completedNCT01613300What this trial is testingStudy of OFATUMUMAB as Part of the Scheme of Reduced Intensity Conditioning in High Risk Non-Hodgkin Lymphoma B PatientsWho this might be right forB-Cell Lymphomas Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea 33
Not applicableStudy completedNCT02452099What this trial is testingImpact of DMSO Concentrations on Hematopoietic Recovery After Autologous HSC Transplantation.Who this might be right forMultiple MyelomaLymphomasLeukemias Maria Sklodowska-Curie National Research Institute of Oncology 150
Testing effectiveness (Phase 2)Study completedNCT01807611What this trial is testingHaploidentical Donor Hematopoietic Progenitor Cell and NK Cell Transplantation for Hematologic MalignancyWho this might be right forLeukemiaLymphoma St. Jude Children's Research Hospital 82
Testing effectiveness (Phase 2)Study completedNCT00599495What this trial is testingMatched Unrelated Donor Stem Cell Transplantation (MUD-SCT) After Dose-reduced Conditioning for Patients With Multiple Myeloma and Relapse After Autologous SCTWho this might be right forMultiple Myeloma Universitätsklinikum Hamburg-Eppendorf 50